The other 74 (74.7%, 74/99) Group 2 cases including 68 of primary breast cancer, 4 of metastatic breast cancers, and 2 of recurrence of breast cancer, showed equivocal HER2 immunostaining (IHC 2+, Fig. 1H). Here, ERBB2 is linked to breast carcinoma.